Thus, while YY1 inhibitors hold promise in GBM treatment, addressing challenges related to the multifaceted nature of YY1, molecular complexity, tumor heterogeneity, drug delivery, and potential resistance is paramount for their successful translation into effective therapeutic strategies for patients with GBM. The gene discussed is YY1; the disease is glioblastoma.